Toll-like receptor 2 (TLR2) and TLR4 differentially activate human dendritic cells

被引:555
作者
Re, F
Strominger, JL
机构
[1] Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA
[2] Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA
关键词
D O I
10.1074/jbc.M105927200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Toll-like receptors (TLRs) mediate cell activation by various microbial products. Here, we demonstrate that activation of dendritic cells by TLR2 or TLR4 agonists, although it led to comparable activation of NF-kappaB and mitogen-activated protein kinase (MAPK) family members, resulted in striking differences in cytokine and chemokine gene transcription, suggesting that TLR2 and TLR4 signaling is not equivalent. A TLR4 agonist specifically promoted the production of the Th1-inducing cytokine interleukin (IL) 12 p70 and the chemokine interferon-gamma inducible protein (IP)-10, which is also associated to Th1 responses. In contrast, TLR2 stimulation failed to induce IL-12 p70 and interferon-gamma inducible protein (IP)-10 but resulted in the release of the IL-12 inhibitory p40 homodimer, producing conditions that are predicted to favor Th2 development. TLR2 stimulation also resulted in preferential induction of IL-8 and p19/IL-23. Involvement of phosphatidylinositol 3-kinase and p38 MAPK in the TLR-mediated induction of several cytokine and chemokine messages was demonstrated using specific inhibitors. Thus, TLRs can translate the information regarding the nature of pathogens into differences in the cytokines and chemokines produced by dendritic cells and therefore may contribute to the polarization of the acquired immune response.
引用
收藏
页码:37692 / 37699
页数:8
相关论文
共 34 条
[1]   Toll-like receptor 2-mediated NF-κB activation requires a RacI-dependent pathway [J].
Arbibe, L ;
Mira, JP ;
Teusch, N ;
Kline, L ;
Guha, M ;
Mackman, N ;
Godowski, PJ ;
Ulevitch, RJ ;
Knaus, UG .
NATURE IMMUNOLOGY, 2000, 1 (06) :533-540
[2]   Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s [J].
Bonecchi, R ;
Bianchi, G ;
Bordignon, PP ;
D'Ambrosio, D ;
Lang, R ;
Borsatti, A ;
Sozzani, S ;
Allavena, P ;
Gray, PA ;
Mantovani, A ;
Sinigaglia, F .
JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 187 (01) :129-134
[3]   Host defense mechanisms triggered by microbial lipoproteins through toll-like receptors [J].
Brightbill, HD ;
Libraty, DH ;
Krutzik, SR ;
Yang, RB ;
Belisle, JT ;
Bleharski, JR ;
Maitland, M ;
Norgard, MV ;
Plevy, SE ;
Smale, ST ;
Brennan, PJ ;
Bloom, BR ;
Godowski, PJ ;
Modlin, RL .
SCIENCE, 1999, 285 (5428) :732-736
[4]   Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction [J].
Chow, JC ;
Young, DW ;
Golenbock, DT ;
Christ, WJ ;
Gusovsky, F .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (16) :10689-10692
[5]   The interleukin-12/interleukin-12-receptor system: Role in normal and pathologic immune responses [J].
Gately, MK ;
Renzetti, LM ;
Magram, J ;
Stern, AS ;
Adorini, L ;
Gubler, U ;
Presky, DH .
ANNUAL REVIEW OF IMMUNOLOGY, 1998, 16 :495-521
[6]   REGULATION OF INTERLEUKIN-12 EXPRESSION IN HUMAN MONOCYTES - SELECTIVE PRIMING BY INTERFERON-GAMMA OF LIPOPOLYSACCHARIDE-INDUCIBLE P35 AND P40 GENES [J].
HAYES, MP ;
WANG, JH ;
NORCROSS, MA .
BLOOD, 1995, 86 (02) :646-650
[7]   A Toll-like receptor recognizes bacterial DNA [J].
Hemmi, H ;
Takeuchi, O ;
Kawai, T ;
Kaisho, T ;
Sato, S ;
Sanjo, H ;
Matsumoto, M ;
Hoshino, K ;
Wagner, H ;
Takeda, K ;
Akira, S .
NATURE, 2000, 408 (6813) :740-745
[8]   Signaling by Toll-like receptor 2 and 4 agonists results in differential gene expression in murine macrophages [J].
Hirschfeld, M ;
Weis, JJ ;
Toshchakov, V ;
Salkowski, CA ;
Cody, MJ ;
Ward, DC ;
Qureshi, N ;
Michalek, SM ;
Vogel, SN .
INFECTION AND IMMUNITY, 2001, 69 (03) :1477-1482
[9]   Cutting edge: Repurification of lipopolysaccharide eliminates signaling through both human and murine toll-like receptor 2 [J].
Hirschfeld, M ;
Ma, Y ;
Weis, JH ;
Vogel, SN ;
Weis, JJ .
JOURNAL OF IMMUNOLOGY, 2000, 165 (02) :618-622
[10]  
Hirschfeld M, 1999, J IMMUNOL, V163, P2382